Integrated Medical Device Data Management Solution Designed to Fill
the Gaps in Electronic Medical Records
IRVINE, Calif.--(BUSINESS WIRE)--Mar. 1, 2016--
Masimo
(NASDAQ: MASI) today announced the debut of Iris™ Gateway, a
server-based software solution for integrating medical device data, at
the HIMSS
(Healthcare Information and Management Systems Society) 2016 Annual
Conference and Exhibition in Las Vegas.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160301005831/en/
Masimo Iris Gateway (Graphic: Business Wire)
Data generated from medical devices remain captive within each device,
and may not be captured in the patients’ electronic medical records
(EMR). Iris Gateway can provide a timely and cost-effective solution by
connecting to existing medical devices and performing the required
translations to move the data from the devices into EMRs. Iris Gateway
can be deployed on a remote server farm or as a server appliance in the
hospital.
The Iris ports on the Root® patient monitor allow other
medical devices (such as infusion pumps, ventilators, patient monitors,
and “smart” beds) to connect to Iris Gateway via Root. Data from these
connected devices can be associated with the patient and entered into
the patient’s EMR, via Iris Gateway. Root with noninvasive blood
pressure and temperature measurements, deployed at the bedside or on a
roll stand, can chart these parameters at the point of care while also
copying the data into an EMR.
“Iris Gateway is an important part of Masimo’s goal of bridging medical
device data silos,” said Joe Kiani, Founder and CEO of Masimo. “It can
be used to connect isolated devices to hospital EMR systems in
high-acuity settings like the OR and the ICU or in low-acuity settings
like medical-surgical units. When data from different medical devices is
more readily available in the patient’s electronic medical record, they
may provide a clearer and more complete picture of the patient. At
Masimo, we are dedicated to providing clinicians with vital information
when they need it most.”
For more information on Masimo and its products, go to www.masimo.com.
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
open architecture patient monitoring and connectivity platform designed
to speed the pace of innovation and reduce the cost of care. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo’s Iris™ Gateway. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Iris™ Gateway, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions with
comparable accuracy and unique advantages, including: immediate and
continuous results that enable earlier treatment without causing
invasive trauma in all patients and in every clinical situation; as well
as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission (“SEC”),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005831/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com